Why the study?
Pulmonary embolism carries high morbidity and mortality if not promptly diagnosed and treated, prompting evaluation of whether HIF-1α levels correlate with clinical course and prognosis across PE risk strata.
Does HIF-1α level correlate with clinical severity and prognosis in patients with pulmonary embolism?
Does HIF-1α level correlate with clinical severity and prognosis in patients with pulmonary embolism?
HIF-1α levels correlate with pulmonary embolism severity and may serve as an early indicator for the need for reperfusion therapy in intermediate high-risk patients.
Answers are grounded in this paper and cite their sources.
HIF-1α may aid PE risk stratification; leaves open routine use pending prospective validation.
Background/aim: Pulmonary embolism (PE) is associated with high morbidity and mortality rates if not diagnosed and treated rapidly. The aim of our study was to investigate the relationship between levels of hypoxia-induced factor-1 alpha (HIF-1α) and clinical course and prognosis in patients with intermediate low-risk, intermediate high-risk, and high-risk PE. Materials and methods: The study included 240 subjects in 4 groups: a healthy control group (n = 60, mean age = 60 ± 15.2, female/male = 30/30 ), intermediate low-risk PE group (n = 60, mean age = 60 ± 12,5, female/male = 27/33), intermediate high-risk PE group (n = 60, mean age = 61,4 ± 14,8, female/male = 36/24), and high-risk PE group (n = 60, mean age = 62,3 ± 15, female/male = 33/27). Plasma HIF-1α levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) kit. Results: Comparison of HIF-1α levels revealed a statistically significant difference between the groups in proportion to clinical scoring (P = 0.001 for all). Comparison of initial HIF-1α and troponin levels in intermediate high-risk PE patients given thrombolytic therapy and those treated with enoxaparin sodium showed that HIF-1α levels were significantly higher in the group that received thrombolytic therapy (P = 0.001), while there was no difference in troponin levels (P = 0.146). Conclusion: HIF-1α can be used in the PE clinical risk stratification and monitoring of PE and may also serve as a valuable early indicator in intermediate high-risk PE, for which early reperfusion therapy is important.
No takes yet. Share an insight, caveat, or question.
Kerget et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: